Ryan McDonald

September 01, 2022

Delivering Sarclisa via an under-the-skin injection may improve the quality of life of patients with pretreated relapsed, refractory multiple myeloma, according to recent research.

September 01, 2022

An expert provides insight on how primary uveal melanoma is often treated and sheds some light on an unmet need in treating the eye cancer.

August 30, 2022

Patients with breast cancer who received post-mastectomy breast reconstruction had similar recurrence rates regardless of the timing of their reconstructive surgery, according to recent study findings.

August 25, 2022

Cervical cancer survivor Ginny Marable heard about a story of a fellow cervical cancer survivor, Tamika Felder, not being able to preserve her fertility. The story moved Marable so much that she and her husband donated their embryos to Felder.

August 18, 2022

A representative of the company developing the investigational CAR-T cell therapy noted that they hypothesize that the combination “has the potential to further enhance efficacy and provide patients with a chemotherapy-sparing, second-line treatment option.”

August 18, 2022

Investigators plan to analyze if treatment with an experimental, CAR-T cell therapy is safe and effective in a small group of patients with relapsed or refractory metastatic colorectal cancer.

August 18, 2022

The FDA has set a date to decide whether or not to approve momelotinib for myelofibrosis, a rare type of blood cancer.

August 17, 2022

A patient with metastatic breast cancer recalls the emotional experience of being among the thousands of attendees who gave a standing ovation in an auditorium in Chicago when the results of the phase 3 DESTINY-Breast04 trial — which recently led to the FDA approval of Enhertu in HER2-low disease — were presented at the 2022 ASCO Annual Meeting.

August 11, 2022

The FDA’s approval of Enhertu marks the first approval of a drug for patients with HER2-mutant unresectable or metastatic non-small cell lung cancer.

August 11, 2022

The FDA’s decision to grant the investigational drug elacestrant a priority review for patients with ER-positive, HER2-negative advanced or metastatic breast cancer was based on data that showed the treatment bested standard-of-care in terms of improving survival.

August 09, 2022

Treatment with Keytruda plus Lenvima did not best Lenvima alone as a first-line treatment option for a group of patients with liver cancer that could not be treated with surgery, according to recently announced study results from a phase 3 clinical trial.

August 08, 2022

Treatment with an investigational drug plus with Libtayo showed encouraging anti-tumor activity in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary data from an early-phase trial.

August 08, 2022

Keytruda plus chemotherapy failed to best the chemotherapy docetaxel alone in patients with metastatic castration-resistant prostate cancer, according to findings of a study of more than 1,000 patients.

August 05, 2022

Treatment with Onivyde failed to best the chemotherapy topotecan in improving overall survival in patients with small cell lung cancer whose disease failed to respond to platinum-based first-line treatment, according to findings from a primary analysis of the phase 3 RESILIENT trial.

August 03, 2022

Enrollment has begun on a phase 3 clinical trial assessing the safety and efficacy of an investigational cell therapy in patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes.

August 03, 2022

The findings add to a growing body of literature that demonstrate coffee and/or tea consumption is not detrimental to breast cancer survivors, according to the study authors.

July 28, 2022

Treatment with Opdivo plus standard of care chemotherapy followed by maintenance Opdivo or Opdivo plus Yervoy failed to elicit survival benefits compared with standard of care chemotherapy alone in patients with previously untreated advanced biliary cancer, which is a rare form of liver cancer.

July 26, 2022

The findings support future studies of assessing the safety and efficacy of the novel drug-chemotherapy combination as a maintenance strategy following stem cell transplantation across a range of blood cancers, according to the study authors.

July 25, 2022

The use of oral paclitaxel and encequidar induced superior outcomes in a group of patients with metastatic breast cancer, compared with paclitaxel delivered intravenously.

July 21, 2022

Treatment with FOLFIRINOX, a combination of several chemotherapy agents, prior to the surgical resection of pancreatic cancer increased survival outcomes when compared to historical data.

July 21, 2022

Investigators are analyzing the novel drug, OP-1250, both as a single-agent treatment option and in combination with Ibrance in patients with recurrent, locally advanced or metastatic ER-positive/HER2-negative breast cancer.

July 19, 2022

A first-in-human trial is investigating the safety and efficacy of the novel CAR-T cell therapy in patients relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

July 15, 2022

The first patient enrolled onto a phase 1 trial has received TCMB07, an investigational drug, for the treatment of cachexia, a severe disorder that may occur in more than half of patients with advanced-stage cancer.

July 15, 2022

The safety, optimal dosage and efficacy of the investigational drug is currently being evaluated in a first-in-human trial in patients with recurrent high-grade glioblastoma, a type of spinal cord and brain cancer.

July 14, 2022

The FDA has permitted the manufacturer of a novel drug to continue a phase 3 clinical trial investigating the effects of treatment with a novel drug in patients with HER2/neu-positive primary breast cancer.

July 14, 2022

Treatment with Cabometyx in combination with Tecentriq induced superior progression-free survival outcomes and disease control rates versus Nexavar alone in patients with advanced hepatocellular carcinoma, the most common type of liver cancer.

July 14, 2022

Amazon and Fred Hutchinson Cancer Center recently launched an early-phase clinical trial to assess the safety and efficacy of a cancer vaccine in the treatment of patients with late-stage skin cancer or hormone receptor-positive, HER2-negative breast cancer.

July 13, 2022

The manufacturer of one of the cancer treatments announced that it is also participating in clinical trials assessing the safety and efficacy of their product in colorectal and endometrial cancer.

July 13, 2022

The use of a chemotherapy-free, combination regimen as a maintenance treatment option was associated with an improvement in survival in a group of patients with advanced pancreatic cancer.

July 12, 2022

The manufacturer of the novel CAR-T cell therapy announced it terminated an early-phase trial investigating the treatment’s efficacy after there was a lack of benefit in patients with relapsed or refractory T-cell lymphoma, a type of blood cancer.